绝经后受体阳性乳腺癌患者高危人群的内分泌治疗课件.pptVIP

* Treat：化疗 Annals of Oncology 18: 1293–1306, 2007 * * 尽管受体阳性患者整体预后较好，但仍有一部分高危患者出现复发转移 Anderson et al. J Clin Oncol. 2001;19:18. While about 10% of ER-positive tumours reveal HER-2 overexpression，HR阳性HER2阳性与HER2阴性患者RFS不同 HER-2–positive patients showed a shorter TTR for both tamoxifen- and anastrozole-treated patients (P.0018 and.0001, respectively) at 5 years (Fig 4). For tamoxifen, the recurrence rate at 5 years was 9.0% for HER-2–negative patients and 18.8% for HER-2– positive patients; for anastrozole, it was 5.9% for HER-2–negative and 19.8% for HER-2–positive patients. Thus, there was no